CRISPR Therapeutics AG — Wall Street Analyst Estimates & Price Targets

CRSP

NASDAQHealthcareBiotechnologyCIK 0001674416crisprtx.comAbout CRSP

Quant grade ?D

Last close · Oct 30, 202651.42−2.84 (−5.23%)

The analysts at a glance

close of Oct 30, 2026

$60.00median of 9 firms' latest targets, 17% above the last close of $51.42

Firms with a target · last 12 months: 9
Lowest – highest target: $50.00 – $82.00
Current grades of 11 firms: positive / neutral / negative: 7 / 4 / 0
Upgrades / downgrades · 12 months: 0 / 0
Consensus revenue growth · next 3 FY: +428% a year

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 12 months · 9 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-15	UBS	$52.00	$80.00	▼ 35%	+4%	+1%
2026-08-06	Goldman Sachs	$55.00	—	—	+5%	+7%
2026-07-08	H.C. Wainwright	$80.00	—	—	+32%	+56%
2026-06-11	Morgan Stanley	$60.00	$33.00	▲ 82%	+21%	+17%
2026-05-13	Bernstein	$56.00	—	—	+6%	+9%
2026-05-11	Evercore ISI	$76.00	$74.00	▲ 3%	+37%	+48%
2026-02-14	Chardan Capital	$76.00	$74.00	▲ 3%	+43%	+48%
2026-02-13	Needham	$82.00	—	—	+52%	+59%
2025-11-11	RBC Capital	$50.00	—	—	-8%	-3%

Current grades

each firm's latest · 11 firms

As of	Firm	Grade
2026-08-31	Citizens	“Market Outperform”
2026-08-31	Needham	“Buy”
2026-08-04	Citigroup	“Buy”
2026-07-08	H.C. Wainwright	“Buy”
2026-05-13	Bernstein	“Market Perform”
2026-03-17	Piper Sandler	“Overweight”
2026-02-17	Chardan Capital	“Buy”
2026-02-13	Evercore ISI	“Outperform”
2026-02-13	TD Cowen	“Hold”
2025-11-11	Baird	“Neutral”
2025-11-11	RBC Capital	“Sector Perform”

Grade changes

last 24 months · 2

Date	Firm	Grade
2025-06-27	Clear Street	“Buy” → “Hold” downgrade
2025-02-14	Evercore ISI	“In Line” → “Outperform” upgrade

20 older than 24 months

2023-12-11	TD Cowen	“Market Perform” → “Underperform” downgrade
2023-10-17	Cantor Fitzgerald	“Overweight” → “Neutral” downgrade
2023-08-18	Citigroup	“Neutral” → “Buy” upgrade
2023-05-09	JMP Securities	“Market Outperform” → “Outperform” revised
2023-04-17	JMP Securities	“Market Outperform” → “Outperform” revised
2023-03-21	Bernstein	“Market Perform” → “Perform” revised
2023-02-27	JMP Securities	“Market Outperform” → “Outperform” revised
2022-08-09	Barclays	“Overweight” → “Equal Weight” downgrade
2022-06-23	Evercore ISI	“Outperform” → “In Line” downgrade
2021-12-07	TD Cowen	“Market Perform” → “Perform” revised
2021-06-14	Citigroup	“Sell” → “Neutral” upgrade
2021-04-21	Jefferies	“Hold” → “Buy” upgrade
2020-12-07	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2020-02-03	Evercore ISI	“Outperform” → “In Line” downgrade
2019-11-12	Oppenheimer	“Perform” → “Outperform” upgrade
2019-03-14	William Blair	“Market Perform” → “Perform” revised
2019-01-28	Goldman Sachs	“Buy” → “Neutral” downgrade
2019-01-22	Citigroup	“Neutral” → “Sell” downgrade
2018-03-08	JMP Securities	“Market Outperform” → “Outperform” revised
2018-01-23	Truist	“Hold” → “Buy” upgrade

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$370.0M	+84762%	-$1.94	—	est. $293.2M+26%	est. -$2.92	18
2024reported	$35.0M	-91%	-$4.34	—	est. $11.2M+213%	est. -$5.16	19
2025reported	$3.5M	-90%	-$6.47	—	est. $7.1M-50%	est. -$6.21	17
2026	$40.4M	+1052%	-$4.36	—	$15.1M–$100.0M	-$5.53–-$3.33	15
2027	$138.6M	+243%	-$3.33	—	$2.0M–$497.7M	-$4.99–-$1.09	14
2028	$518.0M	+274%	-$2.01	—	$29.3M–$3.5B	-$7.08–$9.62	12
2029	$2.6B	+407%	$4.42	—	$170.8M–$13.5B	-$0.95–$28.14	10
2030	$6.7B	+157%	$19.26	+336%	$438.4M–$34.6B	-$4.15–$122.60	6

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.